DaVita Inc. (DVA) Gross Margin: 31.10%
Is DaVita Inc.’s gross margin high or low?
DaVita Inc.'s gross margin of 31.10% is in line with its 5-year average of 30.48%, around the middle of its 5-year range (27.00%–32.91%).
As of Monday, June 15, 2026. 3.82% above its 12-month average of 29.95%.
DVA Gross Margin Chart
DVA Average Gross Margin Chart
DVA Current vs Average Gross Margin Chart
DVA Gross Margin Metrics
GROSS MARGIN
31.10%
GROSS MARGIN AVG TTM
29.95%
GROSS MARGIN AVG 3Y
30.17%
GROSS MARGIN AVG 5Y
30.48%
GROSS MARGIN AVG 10Y
28.74%
GROSS MARGIN AVG 15Y
30.06%
GROSS MARGIN AVG 20Y
30.31%
CURRENT VS TTM AVG
+3.82%
CURRENT VS 3Y AVG
+3.09%
CURRENT VS 5Y AVG
+2.03%
CURRENT VS 10Y AVG
+8.19%
CURRENT VS 15Y AVG
+3.47%
CURRENT VS 20Y AVG
+2.61%
DVA Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.40B | 31.10% | 29.95% | 30.17% | 30.48% |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 64.37% | 63.66% | 64.40% | 64.61% |
| Solventum Corporation (SOLV)vs › | $13.66B | 53.67% | 54.56% | 56.03% | 57.27% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 67.68% | 69.16% | 69.73% | 70.75% |
| Baxter International Inc. (BAX)vs › | $10.77B | 30.11% | 33.76% | 35.72% | 36.84% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.13% | 18.71% | 19.98% | 20.79% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 52.82% | 58.14% | 57.33% | 59.28% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 31.86% | 31.70% | 34.15% | 35.17% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | 69.55% | 62.30% | 54.75% | 44.45% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 51.87% | 52.87% | 53.77% | 54.60% |
Gross Margin Analysis
Gross Margin
31.1%
(Revenue - COGS) / Revenue
DaVita Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. Gross Margin FAQ
- What is the gross margin for DaVita Inc. (DVA)?
- The gross margin for DVA stock is 31.10%.
- Is DaVita Inc.'s gross margin high or low?
- DaVita Inc.'s gross margin of 31.10% is in line with its 5-year average of 30.48%, around the middle of its 5-year range (27.00%–32.91%).
- What is the TTM average gross margin for DaVita Inc. (DVA)?
- The TTM average gross margin for DVA stock is 29.95%.
- What is the 3Y average gross margin for DaVita Inc. (DVA)?
- The 3Y average gross margin for DVA stock is 30.17%.
- What is the 5Y average gross margin for DaVita Inc. (DVA)?
- The 5Y average gross margin for DVA stock is 30.48%.
- What is the 10Y average gross margin for DaVita Inc. (DVA)?
- The 10Y average gross margin for DVA stock is 28.74%.
- What is the 15Y average gross margin for DaVita Inc. (DVA)?
- The 15Y average gross margin for DVA stock is 30.06%.
- What is the 20Y average gross margin for DaVita Inc. (DVA)?
- The 20Y average gross margin for DVA stock is 30.31%.
DaVita Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 27.00% |
| 2024-12-31 | 32.91% |
| 2023-12-31 | 31.47% |
| 2022-12-31 | 29.29% |
| 2021-12-31 | 31.38% |
| 2020-12-31 | 30.84% |
| 2019-12-31 | 30.50% |
| 2018-12-31 | 28.14% |
| 2017-12-31 | 29.76% |
| 2016-12-31 | 22.22% |
| 2015-12-31 | 22.68% |
| 2014-12-31 | 28.73% |
| 2013-12-31 | 30.31% |
| 2012-12-31 | 31.79% |
| 2011-12-31 | 30.89% |
| 2010-12-31 | 27.79% |
| 2009-12-31 | 30.45% |
| 2008-12-31 | 30.74% |
| 2007-12-31 | 31.80% |
| 2006-12-31 | 30.54% |
| 2005-12-31 | 31.56% |
| 2004-12-31 | 30.76% |
| 2003-12-31 | 30.86% |
| 2002-12-31 | 34.34% |
| 2001-12-31 | 33.32% |
| 2000-12-31 | 30.56% |
| 1999-12-31 | 31.28% |
| 1998-12-31 | 35.19% |
| 1997-12-31 | 55.68% |
| 1996-12-31 | 56.36% |
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez